News

Not all cases with rheumatic disease turn up in the rheumatology literature, of course. Test your diagnostic skills on these four puzzlers from other journals. (We present brief descriptions only, with hyperlinks to the original reports.)

prior authorization

Prior authorizations have begun to spread pandemic-like from high-cost biologics to treatments used routinely in rheumatology. The time burden on rheumatologists is insupportable, contends the author, who says it's time to take action.

Registry data show that smokers with spondyloarthropathies have markedly less improvement in disease activity on TNF inhibitors. The evidence also suggests that quitting the smoking habit erases this disadvantage.

A new online journal club, RheumJC, launches with two live chats on Twitter on January 29. It's the first journal club ever in rheumatology, an opportunity for rheumatologists worldwide to discuss important published research.

The FDA has decided will not regulate health apps designed to collect disease information. They're not ready to be useful for rheumatology. Nonetheless, your patients are undoubtedly using them.

In court decision to approve generic colchicine for gout, American College of Rheumatology arguments about the risk to patients of exorbitant pricing may have played an important role. Is this a harbinger of something?

(VIDEO) A gout drug with a new mechanism is showing promise in combination with existing remedies. In this interview, a leader in its progress to market tells why lesinurad could help put an undertreated disorder in a new light.

For treating rheumatoid arthritis not responsive to methotrexate, DMARD combinations beat monotherapy but at greater risk, a summary of recent evidence observes. In another, reviewers disagree about triple therapy.

The benefits of drinking milk have been established in a number of previous studies, but one group recently looked at whether there were specific benefits in helping to delay knee osteoarthritis in women.